Brian Mueller - 25 Feb 2026 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: BMRN
Reported as of: 25 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Feb 2026, 20:28:58 UTC
Prior SEC filing: 13 Feb 2026
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Tae Sang Yoo, Attorney-in-Fact

Key filing fact

Brian Mueller filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 26 Feb 2026.

Key facts

This page summarizes Brian Mueller's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 Feb 2026, 20:28.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001514980 Primary reporting owner

Mueller Brian

Relationship: EVP, Chief Financial Officer
Address: C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL
Signature: /s/ Tae Sang Yoo, Attorney-in-Fact
Signature date: 26 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BMRN transaction

Common Stock

Award

Transaction value: $0
Shares: +6,683
Change %: +6.7%
Price: $0.000000
Shares after: 106,839
Date: 25 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

BMRN transaction

Common Stock

Award

Transaction value: $0
Shares: +7,230
Change %: +6.8%
Price: $0.000000
Shares after: 114,069
Date: 25 Feb 2026
Ownership: Direct
Footnotes: F1, F3, F4

BMRN transaction

Common Stock

Award

Transaction value: $0
Shares: +2,569
Change %: +2.3%
Price: $0.000000
Shares after: 116,638
Date: 25 Feb 2026
Ownership: Direct
Footnotes: F1, F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.

Footnote F2

Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

Footnote F3

Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.

Footnote F4

Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

Footnote F5

Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.